Gentler transplant drug could boost recovery for older cancer patients
NCT ID NCT06799195
Summary
This study is for older adults getting a stem cell transplant for blood cancers. It compares two different doses of a key drug (cyclophosphamide) used to prevent a serious complication called graft-versus-host disease (GVHD). The main goal is to see if a lower dose helps patients feel better and function better in their daily lives after the transplant, without increasing the risk of the cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.